Treatment of Breast Cancer

Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer

This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as copper Cu 64 DOTA-trastuzumab PET, may help predict a patient's response to trastuzumab and pertuzumab before surgery in patients with locally advanced HER2 positive breast cancer.

No pharmaceutical medication involved
Patients and healthy individuals accepted

Radiation - Copper Cu 64-DOTA-Trastuzumab

Given IV

Laboratory Biomarker Analysis

Correlative studies

Biological - Pertuzumab

Given IV

Procedure - Positron Emission Tomography

Undergo PET

Procedure - Therapeutic Conventional Surgery

Undergo surgery

Biological - Trastuzumab

Given IV

Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy